Closed Health
CureCN

Adeno-Associated Virus Vector-Mediated Liver Gene Therapy for Crigler-Najjar Syndrome

€6.2MFunding
72Months
10Partners

Fact sheet

Programme
Horizon 2020 & sub-programmes
Companies
EURICE
Duration
72 months (January 2018 – December 2023)
Project funding
€ 6,249,103.75
Project partners
10
Technology readiness level
2-4
Project website
https://curecn.eu

About the project

Crigler-Najjar (CN) syndrome is a rare recessive disorder caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene for which current treatment options are suboptimal and no permanent cure is available except for liver transplantation. To address the unmet medical need, the CureCN project has the ambitious goal of developing a curative AVV (adeno-associated virus) vector-based gene therapy for CN syndrome. At the heart of the project is an open-label, multicenter clinical trial of AAV8-UGT1A1 gene transfer to prove the safety and efficacy of the therapy in severe CN patients.

Coordinator

Dr Gérald Perret
Association Genethon
Email coordinator